瑞替普酶与尿激酶溶栓治疗中危肺栓塞的临床疗效

Clinical analysis of reteplase or urokinase in the treatment of medium-risk pulmonary thromboembolism

目的对比分析瑞替普酶与尿激酶溶栓治疗中危组肺栓塞临床疗效。方法根据不同的治疗方案将所有患者分成瑞替普酶组(23例)与尿激酶组(39例),将两组患者溶栓效果进行对比与分析。结果治疗后两组D-二聚体、肌钙蛋白T、N-Pro BNP及PASP均较治疗前降低(P<0.05),Pa O2较治疗前升高(P<0.05),两组患者治疗前与治疗后24小时D-二聚体及肌钙蛋白T差值无明显区别(P>0.05),但瑞替普酶组Pa O2、N-Pro BNP、PASP治疗前后差值明显大于尿激酶组(P<0.05)。结论瑞替普酶及尿激酶均可以用于治疗急性中危组PTE,但于住院期间给予中危组肺栓塞患者,瑞替普酶溶栓治疗效果优于尿激酶。

Objective To compare the efficacy of reteplase and urokinase in the treatment of medium-risk pulmonary thromboembolism （ PET ） . Methods 62 patients with medium-risk pulmonary thromboembolism were divided into two groups to be treated with reteplase （23 cases） and urokinase （39 cases）. The effect of thrombolysis was compared. Results The levels of D-dimer, troponin T, NT-ProBNP, and PASP decreased （P〈0. 05）, and the level of PaO2 increased in both groups after the treatment （P〈0. 05）, but the difference was more pronounced in the reteplase group than in the urokinase group （P〈0. 05）. There was no significant difference in D-dimer and troponin T between the two groups before and 24-hour after the treatment （P〉0. 05）. Conclusion Both reteplase and urokinase are safe and effective in the treatment of acute medium-risk PTE, but the curative effect of reteplase is superior to urokinase.